Hema Baskarane
@hema_oncologistMD medicine ( JIPMER), currently pursuing DM Medical oncology in AIIMS New Delhi ..
Similar User
@BhayanaSwati
@akashjha08
@Prabhat_DM_Onco
@annie_baa
@SyedN_Shah
@drneha1pathak
@Mehtaaanuradha
@SauraVermaMD
@SravanDubasi
@BapnaAjay
@sabithap93dot
@sudhirkirar1
@drshubhamsahni
@drneelima_onco
@drnithinsg
☢️💊💉Trimodality therapy offers hope for recurrent T1 bladder cancer after BCG failure! ✅ 3-year freedom from cystectomy: 88% ✅ 3-year OS: 69% ✅Distant metastasis at 3 years: 12% An alternative to radical cystectomy, but safety monitoring is key. #BladderCancer #Oncology…
A must read! A beautifully written editorial on the OS benefit seen in KN522 by @DrHBurstein in @NEJM ! @DFCI_BreastOnc
After turkey and all the trimmings, have a gander at this editorial on IO in TNBC. Immunotherapy for Early-Stage Triple-Negative Breast Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…
Finally out in @ESMO_Open the main findings of my @myESMO #Fellowship research project focused on the identification of predictors of response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in HR+/HER2- #breastcancer. What did we find? A thread 🧵
💫🌟First-line treatment for advanced UCa: Balancing efficacy, safety, patient characteristics, and QoL🌟💫 🎤 Moderator: Dora Niedersüß-Beke 👩⚕️ Presenter: Gunhild von Amsberg #BLADDR24 @OncoAlert @mirrorsmed Key highlights: 🔹 EV + P: Preferred 1L therapy for unresectable/mUC…
💫🌟Looking ahead: BCa management in 2025 - Insights from @KilianGust at #BLADDR24! 🩺🌟💫 @OncoAlert @mirrorsmed 🔹 Urologists embrace technology: device-assisted intravesical chemo enhances care. 🔹 Novel intravesical therapies show promise in NMIBC—Gem/Doc & Erdafitinib…
The results of checkmate 8HW have been published in @NEJM My 2 cents on why I will always prefer nivo-ipi over pembro 1 The checkmate 8hw had less primary progressors. The initial crossover in curves was rectified early. This was due to misdiagnosis of around 13% pts as MSI high
The efficacy of continuing osi with platinum pemetrexed chemo upon progression in patients with met.NSCLC harboring sensitizing EGFR mutations 👉 Continuing osi with next line chemo has PFS benefit with increase time to CNS progression, no OS @ESMO_Open lungcancerjournal.info/article/S0169-…
The results of SONIA are out on @Nature 1L use of palbo did not improve PFS over 2L use, but led to more AEs & costs. An evolving treatment landscape challenges its interpretation— yet it shows that sequencing trials are possible. Congrats to the authors! nature.com/articles/s4158…
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia 👉Obe cel, new 4-1-bb anti cd 19 CAR for refractory B ALL 👉Phase 1b-2 study..127 pts 👉77% overall remission , 55% CR rates @NEJM @RanjitKSMD @Prasshmehta nejm.org/doi/full/10.10…
Experts, including Dr. Melina E. Marmarelis, revealed different approaches to overcoming resistance to immune checkpoint inhibitors. Read more in ILCN: ilcn.org/combining-infl… #LCAM
Day One of hashtag#BLADDR24 Presenter: Dr. Petros Grivas High-risk BCG-unresponsive NMIBC: are we ready to delay/avoid RC? The presentation on high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) explores various treatment options, including radical cystectomy…
💫🌟GREAT TALK! 👏High-risk BCG-unresponsive NMIBC: Are we ready to delay/avoid RC?🌟💫 Presenter: @PGrivasMDPhD #BLADDR24 @OncoAlert @mirrorsmed 🔬 Therapeutic advances: 🔸️Pembrolizumab approved for BCG-unresponsive CIS 🚀 (Keynote-057). 🔸️NadofaraGene Firadenovec: durable…
💫🌟Congress highlights with impact on clinical practice Moderator: Axel Bex #RenalC24 @OncoAlert Localised RCC @bszabados #RENALC24 @OncoAlert @mirrorsmed #RenalC24 #KidneyCancer 🟨 TKI/mTOR inhibitors: Trials include S-TRAC, ASSURE, SORCE, and more. Mixed outcomes! 🟧 CPI…
💫🌟Selecting first-line treatment for advanced clear-cell RCC🌟💫 @schmidingerRCC #RenalC24 @OncoAlert @mirrorsmed 📊 Highlights from #RENALC24: Translating Data to Practice! 1️⃣ Local therapy matters in mRCC 🩺 Surgery or radiotherapy improves survival: 106 vs 59 months.…
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2positive early breast cancer (HELEN-006): a multicentre randomised phase 3 trial @TheLancetOncol thelancet.com/journals/lanon…
Is Ct dna based adjuvant Rx post radical cystectomy the future ? Tombola study design looks impressive @batraatulmd @SuyogCancer @Amolpatel_dr @hema_oncologist
🌟Risk assessment of post-nephrectomy patients Presenter: Philippe Barthélémy🌟 #RENALC24 @OncoAlert @mirrorsmed 📚 KN564: The ONLY positive trial for adjuvant RCC with significant OS and DFS benefits in clear-cell histology. 🎯 Risk Stratification: TNM stage and ISUP grade…
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer out in @Cancer_Cell sciencedirect.com/science/articl… Study highlights the emergence of resistance in metastatic castration-resistant #ProstateCancer (mCRPC) treated with PARP inhibitors (PARPi)💊, particularly in…
#STEAP1-targeted T-cell engager demonstrates efficacy in #mCRPC patients. Dr. William Kelly @JeffersonUniv joins Oliver Sartor, MD @MayoClinic to discuss exciting findings on AMG 509 (Xaluritamig), a STEAP1-targeted T-cell engager for advanced prostate cancer. Promising efficacy…
Exciting new discovery led by @theNCI uncovers a new role of mutant RAS in driving cancer growth – by helping release a nuclear protein (EZH2) into the cytoplasm, which then facilitates the breakdown of a tumor suppressor protein and tumor growth. cancer.gov/news-events/pr…
United States Trends
- 1. Dolphins 38,5 B posts
- 2. #GoPackGo 8.401 posts
- 3. Josh Jacobs 6.639 posts
- 4. McDaniel 6.919 posts
- 5. Datsun 7.895 posts
- 6. Tulane 5.964 posts
- 7. Jordan Love 6.488 posts
- 8. Tyreek 6.376 posts
- 9. Green Bay 9.999 posts
- 10. Jayden Reed 3.412 posts
- 11. #MIAvsGB 8.558 posts
- 12. Jason Garrett 1.240 posts
- 13. Cowboys 45,6 B posts
- 14. Grier 1.658 posts
- 15. Jonnu 2.588 posts
- 16. Achane 3.109 posts
- 17. Wicks 2.764 posts
- 18. Mostert N/A
- 19. Bears 193 B posts
- 20. #GoFins 4.834 posts
Who to follow
-
Swati Bhayana
@BhayanaSwati -
Akashjha
@akashjha08 -
Prabhat Gautam Roy, MD
@Prabhat_DM_Onco -
Annie K Baa
@annie_baa -
Syed Naseem Shah M.D
@SyedN_Shah -
Neha Pathak
@drneha1pathak -
Anuradha Mehta
@Mehtaaanuradha -
Saurav Verma
@SauraVermaMD -
Sravan Kumar Dubasi
@SravanDubasi -
Dr. Ajay Bapna
@BapnaAjay -
Sabitha Paramasivam
@sabithap93dot -
Sudhir Kumar
@sudhirkirar1 -
Shubham Sahni
@drshubhamsahni -
Neelima Ventrapragada
@drneelima_onco -
nithin sg
@drnithinsg
Something went wrong.
Something went wrong.